Eikon Therapeutics to Present Multiple Abstracts at ASCO Annual Meeting

Eikon Therapeutics, a leading biotechnology firm known for integrating advanced engineering in drug discovery and development, is set to present multiple significant findings at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This event, scheduled from May 31 to June 4 in Chicago, will showcase the company’s latest advancements with its clinical-stage TLR 7/8 co-agonist (EIK1001) and PARP1-selective inhibitor (EIK1003).

Highlighting the meeting, an oral presentation will discuss the safety and preliminary efficacy data from a study (NCT03486301) on EIK1001. This Toll-like receptor 7/8 (TLR7/8) co-agonist has been tested in combination with pembrolizumab in patients with advanced solid tumors. The findings indicate that EIK1001 is well-tolerated and exhibits a manageable safety profile. Preliminary results also show promising efficacy across various tumor types, even in patients who had previously not responded to pembrolizumab monotherapy. Dr. Anthony W. Tolcher, of New Experimental Therapeutics (NEXT), will present these findings on June 2, 2024.

Dr. Roy D. Baynes, Chief Medical Officer of Eikon Therapeutics, expressed optimism about these emerging data, highlighting the potential of EIK1001 when combined with pembrolizumab and atezolizumab. The combination therapies underscore the potential benefits of these innovative approaches, especially as EIK1001 progresses into front-line treatments with standard-of-care therapies in non-small cell lung cancer. Additionally, EIK1003, a PARP1-selective inhibitor, has entered phase 1 trials in cancers selected for specific genotypes, furthering Eikon’s commitment to advancing precision medicine.

Eikon Therapeutics will also present three posters at the ASCO Annual Meeting:

1. First-In-Human Phase 1/2 Study of EIK1003: This study involves the PARP1-selective inhibitor (EIK1003) in participants with advanced solid tumors. The presentation, featuring the work of Dr. Guru Sonpavde from AdventHealth Cancer Institute, will take place on June 1, from 9:00 AM to 12:00 PM CDT.

2. Safety and Efficacy of EIK1001 with Atezolizumab: This poster will cover the combination of EIK1001 with atezolizumab in advanced solid tumors. Dr. Manish Patel from the Florida Cancer Specialists & Research Institute will present these findings on June 1, from 9:00 AM to 12:00 PM CDT.

3. Phase 2 Study of EIK1001 with Pembrolizumab and Chemotherapy: This study focuses on EIK1001 in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer. Dr. Dan Costin from White Plains Hospital will present this research on June 3, from 1:30 PM to 4:30 PM CDT.

Eikon Therapeutics will also have a booth (#32116) in the exhibition hall throughout the ASCO Annual Meeting. This presence aims to further disseminate information about their pioneering work in drug discovery and development.

Eikon Therapeutics is dedicated to advancing breakthrough treatments through the integration of engineering and science. Utilizing proprietary discovery technologies such as Nobel Prize-winning super-resolution microscopy, the company aims to visualize and measure protein movements in living cells in real-time. This innovative approach is designed to bring new, vital medicines to patients suffering from serious illnesses. Eikon operates from facilities located in California, New Jersey, and New York.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!